BioSpace News Archive

Deals

Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index

Gracell Biotechnologies Inc. today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

December 16, 2021
·
3 min read
c-LEcta Continues Its Growth in 2021 and Sees Itself Excellently Positioned for the Future With the ENESYZ Technology Platform

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021.

December 16, 2021
·
4 min read
Business

Metrion Biosciences and Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases

Metrion Biosciences Limited and Bioqube Ventures announced that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.

December 16, 2021
·
2 min read
Bio NC

G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company will hire and deploy an additional 20 salespeople, bringing the total number of oncology sales representatives to 34.

December 16, 2021
·
5 min read
Drug Development

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio, Inc. today provided an update from the ongoing Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical hematopoietic stem cell transplant (HSCT).

December 16, 2021
·
5 min read
Bio NC

Inceptor Bio Enters into In-licensing Agreement with University of California, Santa Barbara For CAR-M Platform

Inceptor Bio today announced that it has executed an in-licensing agreement with the University of California, Santa Barbara (UCSB) for an investigational Chimeric Antigen Receptor Macrophage (CAR-M) therapy targeting difficult-to-treat tumors.

December 16, 2021
·
2 min read
Business

Quipt Home Medical Announces Record Preliminary Fourth Quarter 2021 Results and Provides a Business Update

Quipt Home Medical Corp. is very pleased to announce record preliminary financial results for the fourth quarter of 2021, ending September 30, 2021 as well as a business update with respect to recent announcements.

December 16, 2021
·
13 min read
Drug Development

Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

Axcella Therapeutics today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Post COVID-19 Condition and post-acute sequelae of SARS-COV-2 infection (PASC).

December 16, 2021
·
8 min read
Drug Development

Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder

Aptinyx Inc. today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD).

December 16, 2021
·
7 min read
Genetown

Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced significant advances from its RED PLATFORM and across its pipeline of Red Cell Therapeutics (RCTs) at the Company’s first Pipeline and Platform Day.

December 16, 2021
·
9 min read